IVVD
Invivyd, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Invivyd, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Largest filed tie
46.00%
of IVVD revenue · Undisclosed specialty distributor customer
Invivyd has 4 disclosed suppliers and 5 disclosed customers in SEC filings.
SentenceThree specialty distributors accounted for 46%, 23% and 17% of total gross sales for the year ended December 31, 2025.
basisIVVD FY2025 revenue $53M
IVVD 10-Kaccession 0001193125-26-092547
SentenceWe are party to the Adimab Assignment Agreement with Adimab, under which Adimab has assigned to us its rights, title and interest in and to certain of its coronavirus-specific antibodies, including modified or derivative forms thereof, and related intellectual property.
IVVD 10-Kaccession 0000950170-25-042332
SentenceIn November 2022 (the "PHP Effective Date"), we entered into a Master Services Agreement with Population Health Partners, L.P. ("PHP"), pursuant to which PHP agreed to provide services and create deliverables for us as agreed between us and PHP and set forth in one or more work orders under such agreement (the "PHP MSA").
IVVD 10-Kaccession 0000950170-25-042332
SentenceWe have engaged WuXi Biologics, a CDMO, for the development and manufacture of our product candidates for clinical and commercial use.
IVVD 10-Kaccession 0000950170-25-042332
SentenceWe have contracted with WuXi Biologics for the manufacturing of commercial-scale PEMGARDA and VYD2311.
IVVD 10-Kaccession 0000950170-25-042332
SentenceSales to the 3PL Agent accounted for 19% and three specialty distributors accounted for 42%, 24% and 13% of total gross sales for the year ended December 31, 2024.
IVVD 10-Kaccession 0000950170-25-042332
SentenceUnder the license agreement, we will provide Biocon materials and know-how to manufacture and commercialize an antibody treatment based on adintrevimab in India and select emerging markets.
IVVD 10-Kaccession 0000950170-25-042332
SentenceIn order to enable us to execute sales in the U.S. prior to obtaining such licenses, we and an affiliate of the 3PL Agent (the "Title Company") entered into a Temporary Title Model Agreement (the "Temporary Title Model Agreement"), which was an amendment to the 3PL Agreement, so that the Title Company could purchase and take title to the product and sell the product to the specialty distributors who contracted to purchase the product from us.
IVVD 10-Kaccession 0000950170-25-042332
SentenceSales to the 3PL Agent accounted for 19% and three specialty distributors accounted for 42%, 24% and 13% of total gross sales for the year ended December 31, 2024.
IVVD 10-Kaccession 0000950170-25-042332
Invivyd, Inc.
0.59
Expected move
No implied move.